ENGAGE
Brief description of study
This is a phase 2/3, multicenter, randomized, 3-part study investigating the efficacy, safety, tolerability, PK, and immunogenicity of dupilumab in adults and adolescents (12 years of age) with active EoG (with or without EoD).Eosinophilic gastritis (EoG) is a rare, chronic, allergic/immune mediated disease of the stomach, distinct from eosinophilic esophagitis (EoE). EoG is characterized by patchy or diffuse infiltration of eosinophils in the stomach .
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
